Circadian Amplitude Restoration as a Senolytic Switch: Timed NAD+ Boost Coupled to BMAL1-Driven Mitophagy
Hypothesis
We hypothesize that pharmacologically boosting NAD+ at the circadian trough (subjective night) synergizes with tissue‑specific BMAL1 overexpression to restore circadian amplitude, thereby re‑gating mitophagy and suppressing the NFκB‑driven inflammaging loop more effectively than constant NAD+ supplementation.
Mechanistic rationale
- Circadian gating of mitophagy – BMAL1‑CLOCK drives rhythmic expression of PINK1 and Parkin; peak transcription occurs during the early active phase. When amplitude collapses, mitophagy becomes arrhythmic, allowing damaged mitochondria to accumulate and fuel ROS‑NFκB signaling.
- NAD+‑SIRT1 axis – SIRT1 deacetylates BMAL1, enhancing its DNA‑binding affinity; NAD+ troughs reduce SIRT1 activity, weakening the clock and increasing acetylated p65 NFκB activity. Timed NAD+ repletion at the nadir should rescue SIRT1‑BMAL1 interaction without causing chronic SIRT1 overactivation that can blunt stress responses.
- Feed‑forward inflammaging – Elevated NFκB drives CD38 expression, further consuming NAD+ and deepening the trough. Breaking this loop requires simultaneous NAD+ replenishment and BMAL1 reinforcement to restore proper temporal gating of both antioxidant and anti‑inflammatory programs.
Testable predictions
- Prediction 1: In aged mice, timed NAD+ (e.g., NR) administered at ZT14 (subjective night) + AAV‑mediated BMAL1 overexpression in liver will increase circadian amplitude of Bmal1 mRNA (measured by bioluminescence) >2‑fold versus constant NAD+ or BMAL1 alone.
- Prediction 2: The combined intervention will restore rhythmic PINK1/Parkin expression, raising mitophagy flux (mt‑Keima assay) to youthful levels and reducing mitochondrial ROS by ~40%.
- Prediction 3: Consequently, hepatic NFκB p65 acetylation and downstream IL‑6/TNFα serum levels will drop >50% compared with controls, while lifespan extension (median survival) will exceed that of either monotherapy by at least 20%.
Falsifiability
If timed NAD+ plus BMAL1 overexpression fails to improve circadian amplitude, mitophagy rhythm, or inflammasome readouts relative to controls, the hypothesis is refuted. Likewise, if constant NAD+ delivery yields equal or superior outcomes, the temporal specificity claim is invalid.
Translational angle
Human pilot trials could use wearable core‑temperature timing to deliver NR capsules at individual melatonin peak, combined with a liver‑targeted BMAL1 mRNA lipid nanoparticle (LNP) administered weekly. Primary endpoints: 24‑h cortisol rhythm amplitude, plasma NAD+ metabolomics, and circulating senescence‑associated secretory phenotype (SASP) factors.